Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A. ... Tomulić, V. (2019). Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 73. (4), 387-396. doi: 10.1016/j.jacc.2018.10.039
Szarek, Michael, et al. "Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events." Journal of the American College of Cardiology, vol. 73, br. 4, 2019, str. 387-396. https://doi.org/10.1016/j.jacc.2018.10.039
Szarek, Michael, Harvey D. White, Gregory G. Schwartz, Marco Alings, Deepak L. Bhatt, Vera A. Bittner, Chern En Chiang, et al. "Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events." Journal of the American College of Cardiology 73, br. 4 (2019): 387-396. https://doi.org/10.1016/j.jacc.2018.10.039
Szarek, M., et al. (2019) 'Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events', Journal of the American College of Cardiology, 73(4), str. 387-396. doi: 10.1016/j.jacc.2018.10.039
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, i sur.. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology [Internet]. 2019. [pristupljeno 21.08.2024.];73(4):387-396. doi: 10.1016/j.jacc.2018.10.039
M. Szarek, et al., "Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events", Journal of the American College of Cardiology, vol. 73, br. 4, str. 387-396, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:149856. [Citirano: 21.08.2024.]